Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

M.H. Otten, J. Anink, F.H.M. Prince, M. Twilt, S.J. Vastert, R. ten Cate, E.P.A.H. Hoppenreijs, W. Armbrust, S.L. Gorter, P.A. van Pelt, S.S.M. Kamphuis, K.M. Dolman, J.F. Swart, J.M. van den Berg, Y. Koopman-Keemink, M.A.J. van Rossum, N.M. Wulffraat, L.W.A. van Suijlekom-Smit

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)

Abstract

Background Treatment of juvenile idiopathic arthritis (JIA) has changed dramatically since the introduction of biological agents in 1999.

Objective To evaluate trends in prescription patterns of biological agents and the subsequent outcome of JIA.

Methods The Arthritis and Biologics in Children register (multicentre prospective observational study) aimed to include all consecutive patients with JIA in the Netherlands who had started biological agents since 1999. Patients were divided according to year of introduction of first biological agent. Patient characteristics at introduction of the first biological agent and its effectiveness were analysed over 12 years.

Results 335 patients with non-systemic JIA and 86 patients with systemic JIA started a biological agent between 1999 and 2010. Etanercept remained the most often prescribed biological agent for non-systemic JIA; anakinra became first choice for systemic JIA. The use of systemic glucocorticoids and synthetic disease-modifying antirheumatic drugs before biological agents decreased. During these 12 years of observation, biological agents were prescribed earlier in the disease course and to patients with lower baseline JADAS (Juvenile Arthritis Disease Activity Score) disease activity. All baseline disease activity parameters were lowered in patients with non-systemic JIA. In systemic JIA, prescription patterns changed towards very early introduction of biological agents (median 0.4 years of disease duration) in patients with a low number of joints with active arthritis and high erythrocyte sedimentation rates. These changes for both systemic and non-systemic JIA resulted in more patients with inactive disease after 3 and 15 months of treatment.

Conclusions Biological agents are increasingly prescribed, earlier in the disease and in patients with JIA with lower disease activity. These changes are accompanied by better short-term disease outcomes.

Original languageEnglish
Pages (from-to)1379-1386
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number7
Early online date18 Mar 2014
DOIs
Publication statusPublished - Jul 2015

Keywords

  • RHEUMATOID-ARTHRITIS
  • TREATMENT RESPONSE
  • ETANERCEPT
  • THERAPY
  • REMISSION
  • FEATURES
  • TRIAL
  • JIA

Cite this

Otten, M. H., Anink, J., Prince, F. H. M., Twilt, M., Vastert, S. J., ten Cate, R., Hoppenreijs, E. P. A. H., Armbrust, W., Gorter, S. L., van Pelt, P. A., Kamphuis, S. S. M., Dolman, K. M., Swart, J. F., van den Berg, J. M., Koopman-Keemink, Y., van Rossum, M. A. J., Wulffraat, N. M., & van Suijlekom-Smit, L. W. A. (2015). Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Annals of the Rheumatic Diseases, 74(7), 1379-1386. https://doi.org/10.1136/annrheumdis-2013-204641